MICHAEL CHOI: Open Payments
NPI 1881232429 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,049 in 220 payments from 19 companies in 2025. Trend: 2023 $3,940 · 2024 $3,955 · 2025 $8,049
Food & beverage: $5,136Travel & lodging: $2,247Consulting: $555Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 25 | $2,164 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $1,249 |
| E.R. Squibb & Sons, L.L.C. | 14 | $903 |
| Janssen Pharmaceuticals, Inc | 18 | $632 |
| ABBVIE INC. | 27 | $594 |
| Otsuka America Pharmaceutical, Inc. | 24 | $548 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $386 |
| Teva Pharmaceuticals USA, Inc. | 16 | $380 |
| Vanda Pharmaceuticals Inc. | 17 | $344 |
| Alkermes, Inc. | 12 | $273 |
Products named: REXULTI, VRAYLAR, CAPLYTA, SPRAVATO, FANAPT, INGREZZA, INVEGA SUSTENNA, ARISTADA.
Industry payments across CA — which companies pay providers there.
